NCT06132503View on ClinicalTrials.gov

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions
Relapsed or Refractory LymphomasAdvanced Solid Tumor
Interventions
DRUG

LP-284

LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.

Trial Locations (4)

32746

RECRUITING

Florida Cancer Specialists, Lake Mary

37203

RECRUITING

SCRI Oncology Partners, Nashville

84119

RECRUITING

START Mountain Region, West Valley City

90720

RECRUITING

Cancer and Blood Specialists Clinic, Los Alamitos

Sponsors
All Listed Sponsors
lead

Lantern Pharma Inc.

INDUSTRY

NCT06132503 - Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors | Biotech Hunter | Biotech Hunter